Nilotinib Viatris

Nilotinib, the active ingredient in Nilotinib Viatris, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats Philadelphia chromosome‑positive chronic myeloid leukemia in adult patients. GNH USA supplies Nilotinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted tyrosine‑kinase inhibitor used in the management of chronic myeloid leukemia (CML) across disease phases.

Chronic phase CML: improves hematologic and cytogenetic response in newly diagnosed patients. Accelerated phase CML: helps achieve disease control when progression risk increases. Blast phase CML: provides therapeutic benefit as part of combination regimens for advanced disease.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Rash: skin redness or itching. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas. - Severe hepatic injury: marked elevation of liver enzymes. - Neutropenia: dangerously low white‑blood‑cell count. - Thrombocytopenia: reduced platelet levels. - Cardiac failure: signs of reduced heart function.

Before initiating therapy, clinicians should assess baseline cardiac, hepatic and hematologic status and review concomitant medications.

Monitor ECG: check QT interval regularly. Liver function: test transaminases before and during treatment. Blood counts: perform complete blood count monitoring. Avoid strong CYP3A4 inhibitors: these can increase nilotinib exposure. Pregnancy and lactation: risk unknown; avoid use unless clearly needed. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Nilotinib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmia. - Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may lower effectiveness. - Warfarin: may alter anticoagulant control; monitor INR. - Statins metabolized by CYP3A4 (e.g., simvastatin): watch for increased statin exposure.